# 1.0 Submitted By:

Eri Hirumi Staff Regulatory Affairs Specialist Beckman Coulter, Inc. 200 S. Kraemer Blvd., W-110 Brea, California 92822-8000 Telephone: (714) 961-4389 FAX: (714) 961-4234

# 2.0 Date Submitted:

December 23, 2005

3.0 Device Name(s):

3.1 Proprietary Names Dri-STAT $\otimes$ ACP Reagent

# 3.2 Classification Name

Acid phosphatase (total or prostatic) test system (21 CFR $\ S$ 862.1020)

4.0 Predicate Device:

<table><tr><td rowspan=1 colspan=1>Candidate(s)</td><td rowspan=1 colspan=1>Predicate</td><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>DocketNumber</td></tr><tr><td rowspan=1 colspan=1>Dri-STAT® ReagentACP on SynchronSystems</td><td rowspan=1 colspan=1>Dri-STAT® ReagentACP On CobasFara</td><td rowspan=1 colspan=1>BeckmanCoulter, Inc.*</td><td rowspan=1 colspan=1>K821674</td></tr></table>

\*Beckman Coulter, Inc., Brea, CA

# 5.0 Description:

The Dri-STAT $\circledast$ Reagent ACP may be used on the family of Synchron Systems. The reagent kit contains 20 reagent bottles that needs to be manually transferred into a Beckman Coulter User-Define Cartridge. Also with 1 bottle of Acetate Buffer. The reagent kit contains a bottle of Acetate Buffer along with a sample treatment.

# 6.0 Intended Use:

Dri-STAT® Reagent ACP is intended for use in the in vitro diagnostic determination of total acid phosphatase and non-prostatic acid phosphatase in human serum as a User Defined Reagent (UDR) application on SYNCHRON® Systems.

# 7.0 Comparison to Predicate(s):

The following table shows similarities and differences between the predicates identified in Section 4.0 of this summary.

<table><tr><td rowspan=1 colspan=1>Similarities</td><td></td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=6 colspan=1>Same as Beckman CoulterDri-STAT® ACP Reagent,on Cobas Fara</td></tr><tr><td rowspan=1 colspan=1>Methodology</td></tr><tr><td rowspan=1 colspan=1>Reactive Ingredients</td></tr><tr><td rowspan=1 colspan=1>Sample Types</td></tr><tr><td rowspan=1 colspan=1>Shelf Life</td></tr><tr><td rowspan=1 colspan=1>Reaction Type</td></tr><tr><td rowspan=1 colspan=1>s         Differences</td><td></td></tr><tr><td rowspan=1 colspan=1>Instrument Platforms</td><td rowspan=1 colspan=1>Cobas Fara (Predicate) vs.Synchron® Systems (candidate)</td></tr><tr><td rowspan=2 colspan=1>Reference Intervals @ 37°CTotal Acid Phosphatase(TACP)</td><td rowspan=1 colspan=1>≤5.4      U/L male on predicate</td></tr><tr><td rowspan=1 colspan=1>2.5-11.7U/L male per literature</td></tr><tr><td rowspan=2 colspan=1>Reference Intervals @ 37°Non-prostatic AcidPhosphatase (NPAP)</td><td rowspan=1 colspan=1>≤1.2      U/L male on predicate</td></tr><tr><td rowspan=1 colspan=1>0.2 - 3.5 U/L male per literature</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>405 nm on predicate410 nm on candidate</td></tr><tr><td rowspan=2 colspan=1>Analytical Range</td><td rowspan=1 colspan=1>Predicate: 0 - 38 U/L</td></tr><tr><td rowspan=1 colspan=1>Candidate: 2 - 38 U/L</td></tr><tr><td rowspan=1 colspan=1>Reaction Volumes</td><td rowspan=1 colspan=1>0.20; 3.00; 0.025 mL on predicate25; 200; 6 μL on candidate</td></tr></table>

# 8.0 Summary of Performance Data:

The data in the Premarket Notification on safety and effectiveness supports a finding of substantial equivalence to chemistry test systems already in commercial distribution. Equivalence is demonstrated through method comparison, linearity, and imprecision experiments.

Dri-STAT Reagent ACP Method Comparison Study Results   

<table><tr><td rowspan=1 colspan=1>Candidate Method</td><td rowspan=1 colspan=1>SampleType</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Inter-cept</td><td rowspan=1 colspan=1>R</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Predicate Method</td></tr><tr><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Synchron LXSystems</td><td rowspan=1 colspan=1>SerumTACP</td><td rowspan=1 colspan=1>1.093</td><td rowspan=1 colspan=1>0.143</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Cobas Fara</td></tr><tr><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Synchron LXSystems</td><td rowspan=1 colspan=1>SerumNPAP</td><td rowspan=1 colspan=1>1.066</td><td rowspan=1 colspan=1>-0.197</td><td rowspan=1 colspan=1>0.979</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Cobas Fara</td></tr><tr><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Synchron CXSystems</td><td rowspan=1 colspan=1>SerumTACP</td><td rowspan=1 colspan=1>1.075</td><td rowspan=1 colspan=1>0.460</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>94</td><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Cobas Fara</td></tr><tr><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Synchron CXSystems</td><td rowspan=1 colspan=1>SerumNPAP</td><td rowspan=1 colspan=1>1.088</td><td rowspan=1 colspan=1>-0.172</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>Dri-STATReagent ACPOn Cobas Fara</td></tr></table>

Dri-STAT Reagent ACP Estimated Imprecision - TACP   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>S.D. (U/L)</td><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=5>Within-Run Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>3.81</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>4.72</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 2</td><td rowspan=1 colspan=1>20.6</td><td rowspan=1 colspan=1>0.26</td><td rowspan=1 colspan=1>1.28</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 3</td><td rowspan=1 colspan=1>37.0</td><td rowspan=1 colspan=1>0.50</td><td rowspan=1 colspan=1>1.35</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>35.5</td><td rowspan=1 colspan=1>0.58</td><td rowspan=1 colspan=1>1.63</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=5>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>3.81</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>4.99</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 2</td><td rowspan=1 colspan=1>20.6</td><td rowspan=1 colspan=1>0.35</td><td rowspan=1 colspan=1>1.70</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Serum Control 3</td><td rowspan=1 colspan=1>37.0</td><td rowspan=1 colspan=1>0.64</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>35.5</td><td rowspan=1 colspan=1>0.91</td><td rowspan=1 colspan=1>2.56</td><td rowspan=1 colspan=1>80</td></tr></table>

Dri-STAT Reagent ACP Estimated Imprecision - NPAP   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Mean (U/L)</td><td rowspan=1 colspan=1>S.D. (U/L)</td><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>N</td></tr><tr><td rowspan=1 colspan=2>Within-Run Imprecision</td><td rowspan=1 colspan=3>mprecision</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>8.08</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>8.11</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=5>Total Imprecision</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>2.60</td><td rowspan=1 colspan=1>0.21</td><td rowspan=1 colspan=1>8.08</td><td rowspan=1 colspan=1>80</td></tr><tr><td rowspan=1 colspan=1>Human Pool</td><td rowspan=1 colspan=1>2.96</td><td rowspan=1 colspan=1>0.29</td><td rowspan=1 colspan=1>9.80</td><td rowspan=1 colspan=1>80</td></tr></table>

This summary of safety and effectiveness is being submitted in accordance with the requirements of the Safe Medical Device Act of 1990 and the implementing regulation 21 CFR 807.92.

Mr. Eri Hirumi   
Staff Regulatory Affairs Specialist Beckman Coulter, Inc.   
200 S. Kraemer Blvd.   
M/S W-110   
Brea, CA 92822-8000

Re: k053612 Trade/Device Name: Dri-STAT $\textsuperscript { \textregistered }$ Reagent ACP Regulation Number: 21 CFR§862.1020 Regulation Name: Acid Phosphatase (total or prostatic) test system Regulatory Class: Class II Product Code: CKB Dated: March 22, 2006 Received: March 23, 2006

Dear Mr. Hirumi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA). it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) paoiT  nul ualc urvi y marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/e736c5ef405499831f53ccbb54d9d931695663f8ef07f0b0edf4961081fca221.jpg)

Alberto Gutierez, Ph.D. —   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K053612

# Device Name: Dri-STAt® REAGENT ACP

Indications For Use:

Dri-STAT® Reagent ACP is intended for use in the in vitro diagnostic determination of total acid phosphatase and non-prostatic acid phosphatase in human serum as a User Defined Reagent (UDR) application on SYNCHRON® Systems.

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Office Diagnostic Devi Evaly fat KU53012

Page 1 of